Crinetics Pharmaceuticals.
company in San Diego, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 44
What's happening
One to three months ago
-
Crinetics Pharmaceuticals and Osaka are being compared as healthcare companies.Some support1 report
-
Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.Some support2 reports
-
The Strait of Hormuz incident is raising oil prices while various tech and pharmaceutical stocks are experiencing market movements.Some support16 reports1 development inside
Gone quiet
No new reports in 90+ days-
Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.Well supported10 reports
-
TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.Some support1 report
-
Jefferies Financial Group issued a report regarding the stock of Crinetics Pharmaceuticals on July 7, 2026.Some support1 report
-
Nvidia, Crinetics Pharmaceuticals, Micron Technology, and Samsung Electronics are all involved in the AI chip market, with Samsung reporting Q2 performance in Seoul.Some support4 reports
-
Crinetics Pharmaceuticals filed transaction details with the SEC on June 18, 2026.Some support1 report
-
Crinetics Pharmaceuticals benefits from market conditions created by Trump-era tariffs and onshoring policies, while Camurus faces competitive rejection.Some support1 report
-
Biogen reported positive data on the salanersen study on July 3, 2025, involving the medical drugs industry and gaining attention from Zacks.Speculative2 reports
-
Crinetics Pharmaceuticals announced results from San Diego on July 11, 2025. Natalie Badillo heads Corporate Communications and Gayathri Diwakar heads Investor Relations.Some support1 report
-
Crinetics Pharmaceuticals presented new data at the ENDO 2025 conference on July 14, 2025.Some support2 reports
-
Goldman Sachs initiated coverage of Crinetics Pharmaceuticals with a Hold rating on July 16, 2025.Some support1 report
-
Crinetics Pharmaceuticals' stock price is expected to be impacted by an anticipated decline in earnings.Some support2 reports
-
Crinetics Pharmaceuticals operates in the drug sector, and on August 8, 2025, its stock underperformed the general market index. Investors used Zacks Rank to track earnings revisions.Some support2 reports
-
Crinetics Pharmaceuticals announced grants received from San Diego on August 12, 2025.Some support2 reports
-
The FDA granted Orphan Drug Designation for a drug developed by Crinetics Pharmaceuticals for the treatment of Congenital Adrenal Hyperplasia (CAH).Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Crinetics Pharmaceuticals this week
News at the entities that move Crinetics Pharmaceuticals most-
Vertex StructuralA Vertex employee won an Info-Tech award, the company is listed on Nasdaq, and Sarah Vlasic leads Leadership Circles at the University of Colorado Boulder.Moves Crinetics Pharmaceuticals
-
Vertex Pharmaceuticals StructuralFinancial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.Moves Crinetics Pharmaceuticals
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Crinetics Pharmaceuticals
-
SEC StructuralSurgery Partners and Fifth Third Bancorp announced increased holdings in company stock, requiring filing with the SEC on September 8, 2026.Moves Crinetics Pharmaceuticals
-
Donald Trump OperationalTrump's task force targets fraud in Minnesota, spurred by Nick Shirley's reporting and leading to FBI investigations.Moves Crinetics Pharmaceuticals
-
European Medicines Agency StructuralGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Crinetics Pharmaceuticals
Connections
The 21 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Vertex Structural
Vertex acquired Crinetics Pharmaceuticals, establishing a parent-subsidiary relationship for strategic growth and commercial platform expansion.
-
Vertex Pharmaceuticals Structural
Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals in a $10 billion deal, establishing a parent-subsidiary relationship.
-
FDA Structural
The FDA formally regulates and approves drug applications from Crinetics Pharmaceuticals, determining its market viability.
-
representative Transactional
The representative has engaged in the buying and selling of shares in Crinetics Pharmaceuticals.
-
SEC Structural
Crinetics Pharmaceuticals is subject to formal regulatory oversight by the SEC, requiring the filing of transaction details.
-
Donald Trump Operational
Crinetics Pharmaceuticals benefits from the business environment created by Donald Trump's policy proposals, specifically regarding tariffs and onshoring.
-
European Medicines Agency Structural
EMA regulates Crinetics Pharmaceuticals, requiring product approval for market entry.
-
Nvidia Mentioned together
The entities are co-mentioned based on their shared involvement in the technology and pharmaceutical sectors.
Show all 21 connections
-
San Diego Shared context
Crinetics Pharmaceuticals is based in San Diego and conducts its operations and reports results from the city.
-
Joseph Schwartz Mentioned together
A is a market analyst whose coverage includes issuing Outperform ratings on B.
-
Osaka Shared context
The evidence suggests both entities are healthcare companies whose competitive landscape is being compared.
-
Camurus Operational
Camurus and Crinetics Pharmaceuticals are active competitors in the US pharmaceutical market.
-
European Commission Structural
Crinetics Pharmaceuticals required formal approval from the European Commission for its product candidates to operate in the European market.
-
TD Cowen Mentioned together
TD Cowen provided market coverage of Crinetics Pharmaceuticals by reissuing a hold rating.
-
New York Shared context
Crinetics' acquisition activity is reported in the context of the broader pharmaceutical market.
-
Neurocrine Biosciences Mentioned together
Co-mention observed in articles discussing the pharmaceutical sector, though the specific evidence relates to Neurocrine's unrelated acquisition of Soleno Therapeutics.
-
Intel Mentioned together
Intel and Crinetics Pharmaceuticals are co-mentioned in articles describing their involvement in the pharmaceutical and technology sectors.
-
Gil Cisneros Transactional
Gil Cisneros executed a share sale of Crinetics Pharmaceuticals.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides financial analysis and reports on Crinetics Pharmaceuticals stock.
-
Novartis Mentioned together
The provided evidence does not describe a relationship between Crinetics Pharmaceuticals and Novartis.
-
Samsung Electronics Mentioned together
The provided evidence does not describe any relationship between Samsung Electronics and Crinetics Pharmaceuticals.
History
Events by the month they beganAugust 2026
2 eventsJuly 2026
5 events- The Strait of Hormuz incident is raising oil prices while various tech and pharmaceutical stocks are experiencing market movements.
- Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.
- TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.
- Jefferies Financial Group issued a report regarding the stock of Crinetics Pharmaceuticals on July 7, 2026.
- Nvidia, Crinetics Pharmaceuticals, Micron Technology, and Samsung Electronics are all involved in the AI chip market, with Samsung reporting Q2 performance in Seoul.
June 2026
10 events- Crinetics Pharmaceuticals filed transaction details with the SEC on June 18, 2026.
- Crinetics Pharmaceuticals benefits from market conditions created by Trump-era tariffs and onshoring policies, while Camurus faces competitive rejection.
- Biogen reported positive data on the salanersen study on July 3, 2025, involving the medical drugs industry and gaining attention from Zacks.
- Crinetics Pharmaceuticals announced results from San Diego on July 11, 2025. Natalie Badillo heads Corporate Communications and Gayathri Diwakar heads Investor Relations.
- Crinetics Pharmaceuticals presented new data at the ENDO 2025 conference on July 14, 2025.
- Goldman Sachs initiated coverage of Crinetics Pharmaceuticals with a Hold rating on July 16, 2025.
- Crinetics Pharmaceuticals' stock price is expected to be impacted by an anticipated decline in earnings.
- Crinetics Pharmaceuticals operates in the drug sector, and on August 8, 2025, its stock underperformed the general market index. Investors used Zacks Rank to track earnings revisions.
- Crinetics Pharmaceuticals announced grants received from San Diego on August 12, 2025.
- The FDA granted Orphan Drug Designation for a drug developed by Crinetics Pharmaceuticals for the treatment of Congenital Adrenal Hyperplasia (CAH).